
ALK
Os inibidores de ALK são compostos que especificamente visam e inibem a quinase do linfoma anaplásico (ALK), uma tirosina quinase receptora envolvida no desenvolvimento e progressão de certos cânceres, incluindo o câncer de pulmão de células não pequenas e o neuroblastoma. Ao inibir ALK, esses compostos bloqueiam vias de sinalização que promovem o crescimento e a sobrevivência das células tumorais. Na CymitQuimica, oferecemos inibidores de ALK para apoiar sua pesquisa em oncologia, terapias direcionadas contra o câncer e transdução de sinal.
Foram encontrados 147 produtos para "ALK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ALK/ROS1-IN-3
ALK/ROS1-IN-3 (compound C01) is a dual inhibitor targeting ROS1 and ALK, with IC50 values of 42.3 nM for ROS1G2032R and 49.1 nM for ALKG1202R.Fórmula:C32H32N4O2Cor e Forma:SolidPeso molecular:504.25253ALK5 Inhibitor II (hydrochloride)
CAS:ALK5 Inhibitor II has IC50s: 4 nM (auto), 18 nM (TGF-β assay), 23 nM (binding, HepG2).Fórmula:C17H13N5·HClPureza:98%Cor e Forma:SolidPeso molecular:323.8ALKBH5-IN-5
CAS:ALKBH5-IN-5 is a highly selective, potent and covalently binding ALKBH5 inhibitor that alters m6A levels on mRNA, induces apoptosis, antitumo.Fórmula:C13H13NO3Pureza:99.54%Cor e Forma:SolidPeso molecular:231.25Ref: TM-T203011
5mg34,00€10mg46,00€1mL*10mM (DMSO)49,00€25mg84,00€50mg120,00€100mg178,00€200mg268,00€ALK/ROS1-IN-5
ALK/ROS1-IN-5 (compound X4) is a selective inhibitor of ALK and ROS1 kinases, with IC50 values of 0.512 μM for ALK and 0.766 μM for ROS1. It inhibits H2228 cells with an IC50 of 0.034 μM and induces apoptosis in cancer cells in a dose-dependent manner. Additionally, ALK/ROS1-IN-5 effectively suppresses the expression of p-ALK and p-ERK in cancer cells.Fórmula:C32H28F2N4O3Cor e Forma:SolidPeso molecular:554.586Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Pureza:98%Cor e Forma:Odour SolidPROTAC ALK degrader-3
PROTAC ALK degrader-3 (4B) is an orally active PROTAC-based ALK degrader, efficiently inducing sustained degradation of ALK fusion protein and significant inhibition of downstream pathways in Karpas 299 cells with an IC50 of 119.33 nM. This compound exhibits antitumor activity.Fórmula:C50H60ClN9O7SCor e Forma:SolidPeso molecular:966.59dALK-3
dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.Fórmula:C39H45ClN7O5PCor e Forma:SolidPeso molecular:758.245ALK degrader 2
ALK degrader 2 is an orally active ALK degrader that reduces EML4-ALK protein levels (DC50= 8 nM) and nucleophosmin (NPM)-ALK protein levels (DC50= 102 nM). It facilitates ALK degradation through the Hsp70 chaperone system and the ubiquitin-proteasome pathway. In H3122 cells, ALK degrader 2 causes significant cell cycle arrest at the S phase and induces apoptosis. Additionally, it demonstrates antitumor activity in mice with H3122 xenograft tumors. ALK degrader 2 is a useful compound in researching non-small cell lung cancer (NSCLC).Cor e Forma:Odour Solid2-Keto Crizotinib
CAS:2-Keto Crizotinib is an active lactam metabolite of crizotinib.Fórmula:C21H20Cl2FN5O2Pureza:98%Cor e Forma:SolidPeso molecular:464.32TL13-12
CAS:TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).Fórmula:C45H53ClN10O10SPureza:98%Cor e Forma:SolidPeso molecular:961.49TL13-110
CAS:Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).Fórmula:C49H62ClN9O9SCor e Forma:SolidPeso molecular:988.59TL13-112
CAS:TL13-112 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.14 nM).Fórmula:C49H60ClN9O10SPureza:98%Cor e Forma:SolidPeso molecular:1002.57ALK-IN-9
CAS:ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.Fórmula:C20H21FN6O3Cor e Forma:SolidPeso molecular:412.425LAE-102
LAE-102 is a monoclonal antibody that acts as an antagonist of activin receptor II-A (ACTRIIA/ACVR2). It shows potential for research in the fields of endocrine and metabolic disorders, oncology, and respiratory diseases.Cor e Forma:Odour LiquidALK2-IN-6
CAS:ALK2-IN-6 is a potent and selective ALK2 inhibitor with an IC50 of 9 nM. ALK2-IN-6 exhibits excellent brain permeability and effectively suppresses bone morphogenetic protein signaling across various preclinical cancer models for the treatment of diffuse intrinsic pontine glioma.Fórmula:C26H31N3O3Pureza:99.97%Cor e Forma:Gray SolidPeso molecular:433.54ALK-IN-12
CAS:ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.Fórmula:C24H30ClN6O2PCor e Forma:SolidPeso molecular:500.97LDN 193688
CAS:LDN 193688 is a BMP kinase inhibitor preferential for the ALK2 site, acting by binding to the ALK site,progressive osseous fibrodysplasia.Fórmula:C22H16N4OPureza:99.48%Cor e Forma:SolidPeso molecular:352.39CPD-1224
CAS:CPD-1224, an oral ALK inhibitor derivative, binds cereblon, targets EML4-ALK fusions, and degrades ALK plus L1196M/G1202R mutants.Fórmula:C43H47ClN8O7SCor e Forma:SolidPeso molecular:855.4FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Cor e Forma:LiquidRef: TM-L1610
1mgA consultar10μL*10mM (DMSO)A consultar20μL*10mM (DMSO)A consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarCeritinib-amide-C3-acid
CAS:Ceritinib-amide-C3-acid is a ligand-linker conjugate of a target protein. It consists of the protein ligand Ceritinib and a linker used for connecting an E3 ligase ligand. Ceritinib-amide-C3-acid is useful in the synthesis of [TD-004].Fórmula:C33H42ClN5O6SPeso molecular:672.24

